Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Pediatric Genomic Medicine, |
RCV000515094 | SCV000609748 | uncertain significance | not provided | 2017-04-28 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001865687 | SCV002168175 | uncertain significance | Peroxisome biogenesis disorder | 2022-10-03 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 361 of the PEX6 protein (p.Thr361Ala). This variant is present in population databases (rs146025917, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with PEX6-related conditions. ClinVar contains an entry for this variant (Variation ID: 445406). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PEX6 protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002481656 | SCV002791572 | uncertain significance | Peroxisome biogenesis disorder 4A (Zellweger); Peroxisome biogenesis disorder 4B; Heimler syndrome 2 | 2021-12-09 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001276736 | SCV001463264 | uncertain significance | Zellweger spectrum disorders | 2019-10-28 | no assertion criteria provided | clinical testing |